Skip to content
MarketScale
‹ Back to IndustriesSciences

The Secret Science To Harnessing the Power of Probiotics using Prebiotics

The podcast discusses the importance of prebiotics in enhancing the efficacy of probiotics for gut health. With insights from Deerland Probiotics & Enzymes, it highlights the science, consumer habits, and the challenges in marketing prebiotics effectively. Key developments include Deerland's breakthrough in reducing required prebiotic dosage for beneficial effects.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · Daniel Litwin PodcastJohn Davidson PodcastJohn Deaton PodcastPromoted Content
Share
The Secret Science To Harnessing the Power of Probiotics using Prebiotics

Key takeaways

01

Prebiotics are essential for maximizing the benefits of probiotics in gut health.

02

Deerland has developed a prebiotic that requires only 15 mg per day for efficacy.

03

Consumer education on prebiotics is critical as the market for digestive health products grows.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us. But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy? The answer — Prebiotics.

Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences Podcast are scientists John Davidson, Director of Innovation & Education for Deerland Probioics & Enzymes, and John Deaton, VP of Science & Technology for Deerland Probiotics & Enzymes. This episode talks about how and why it is important to prime your gut with prebiotics, in order to truly harness the power of probiotics. From a marketing standpoint “probiotics were first out of the gate,” Deaton says, “but it’s not as simple as consuming a probiotic.”

Probiotic organisms are not very shelf-stable, nor very resilient to our stomach acids. This is why a prebiotic is so important. As non-living organisms, prebiotics are a food source or a compound, and much easier to manage in application. But, for real efficacy, prebiotics must be consumed in large doses. Herein lies the crux that Deerland has tackled head-on.

How do we provide a prebiotic that is small, consumable, and reduces the main side effect of gas, caused by fermentation in the gut? Davidson explains the groundbreaking science of their prebiotic, which is “based on bacteria phase technology.” Davidson and Deaton have reduced the dosage of necessary prebiotics from over 1 gram, to “Only 15 mg a day required for efficacy.”

In short, Deerland has “Really revolutionized the whole prebiotic space.” Says Davidson. The science is in, but the hard work isn’t over. “Consumer education is gonna be the key,” says Davidson. Consumers may love the idea of probiotics, but don’t know that their efforts are futile without the symbiotic help of prebiotics.

Luckily, the probiotic and prebiotic markets are only growing, with business owners taking note of this health phenomenon. Deerland Probiotics & Enzymes is ready with their prebiotic solution, PreforPro.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

JD
John Davidson

Director of Innovation & Education

Deerland Probiotics & Enzymes

John Davidson is the Director of Innovation & Education at Deerland Probiotics & Enzymes. He focuses on advancing the understanding and application of probiotics and prebiotics in the health market.

JD
John Deaton

VP of Science & Technology

Deerland Probiotics & Enzymes

John Deaton is the Vice President of Science & Technology at Deerland Probiotics & Enzymes, where he leads scientific efforts to improve probiotics' efficacy with innovative prebiotic solutions.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512